Figure 3
The studies included to investigate CDKN2A methylation status between 358 patients with pancreatic cancer and 201 normal individuals.
The combined OR was 17.19 (95% CI: 8.72–33.86; Z = 5.26; p < 0.00001).
Figure 3 | Scientific Reports
The studies included to investigate CDKN2A methylation status between 358 patients with pancreatic cancer and 201 normal individuals.
The combined OR was 17.19 (95% CI: 8.72–33.86; Z = 5.26; p < 0.00001).
